Silvia Shardonofsky
Montreal, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Minimal Blood Pressure Effects of Intranasal Etripamil for Paroxysmal Supraventricular Tachycardia.
Journal: JACC. Advances
Published: February 10, 2026
Self-Administered Etripamil Nasal Spray Slows Ventricular Rate in Patients With Atrial Fibrillation: A Post Hoc Analysis of the NODE-303 Study.
Journal: Journal of cardiovascular electrophysiology
Published: October 09, 2025
Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE-303 Open-Label Study.
Journal: Journal of cardiovascular electrophysiology
Published: April 30, 2025
Self-Administered Etripamil Nasal Spray Relieved Symptoms, Decreased Heart Rate, and Reduced Medical Interventions During Atrioventricular Nodal-Dependent Paroxysmal Supraventricular Tachycardia.
Journal: Circulation. Arrhythmia and electrophysiology
Published: November 27, 2024
Multicenter, Phase 2, Randomized Controlled Study of the Efficacy and Safety of Etripamil Nasal Spray for the Acute Reduction of Rapid Ventricular Rate in Patients With Symptomatic Atrial Fibrillation (ReVeRA-201).
Journal: Circulation. Arrhythmia and electrophysiology
Published: November 11, 2023
Rationale and design of the NODE-303 study: evaluating the safety of symptom-prompted, self-administered etripamil for paroxysmal supraventricular tachycardia episodes in real-world settings.
Journal: American heart journal
Published: October 24, 2023
Etripamil Nasal Spray for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-Term Follow-Up: Results From the NODE-302 Study.
Journal: Journal of the American Heart Association
Published: September 27, 2023
Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.
Journal: Lancet (London, England)
Published: February 08, 2023
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301).
Journal: Circulation. Arrhythmia and electrophysiology
Published: November 28, 2022
Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia.
Journal: American heart journal
Published: January 18, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026